ARAMINE Drug Patent Profile

« Back to Dashboard

Which patents cover Aramine, and when can generic versions of Aramine launch?

Aramine is a drug marketed by Merck and is included in one NDA.

The generic ingredient in ARAMINE is metaraminol bitartrate. There is one drug master file entry for this compound. Additional details are available on the metaraminol bitartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aramine

A generic version of ARAMINE was approved as metaraminol bitartrate by AZURITY on August 24^th, 2021.

Summary for ARAMINE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	61
DailyMed Link:	ARAMINE at DailyMed

US Patents and Regulatory Information for ARAMINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	ARAMINE	metaraminol bitartrate	INJECTABLE;INJECTION	009509-002	Dec 22, 1987		DISCN	Yes	No

ARAMINE Market Dynamics and Financial Trajectory: Metaraminol Injection Analysis

Last updated: October 24, 2026

ARAMINE is the former brand name for metaraminol, an injectable sympathomimetic used to increase blood pressure in acute hypotension. Its commercial profile is unlike that of a modern branded pharmaceutical: demand is hospital-based, volumes are limited, generic substitution is established, and public financial disclosures do not separately report ARAMINE revenue. The economic value lies primarily in reliable supply, hospital formulary access, manufacturing capacity, and shortage-period pricing rather than patent exclusivity.

The active ingredient has no meaningful current biosimilar pathway because metaraminol is a small-molecule drug. Its competitive risk comes from generic injectable manufacturers, compounded alternatives, related vasopressors such as phenylephrine and norepinephrine, and changes in hospital purchasing contracts.

What is ARAMINE and how is metaraminol used?

ARAMINE is associated with metaraminol bitartrate injection, a direct and indirect adrenergic agent used to treat acute hypotension. The drug produces vasoconstriction and raises blood pressure, making it relevant to anesthesia, perioperative care, emergency medicine and selected critical-care settings. U.S. labeling describes intravenous and intramuscular administration, with dosing adjusted to the patient’s hemodynamic response (DailyMed, n.d.-a).

Attribute	ARAMINE / metaraminol
Active ingredient	Metaraminol bitartrate
Drug class	Sympathomimetic vasopressor
Primary dosage form	Sterile injectable solution
Typical setting	Hospital and procedural care
Main clinical role	Treatment of acute hypotension
U.S. commercial model	Generic and institutional purchasing
Biosimilar exposure	None
Primary competitors	Phenylephrine, norepinephrine, ephedrine and other vasopressors
Main commercial constraint	Manufacturing and supply reliability

ARAMINE should not be analyzed as a conventional retail prescription brand. Hospital pharmacies and group purchasing organizations generally buy injectable vasopressors through institutional contracts. Product selection depends on concentration, vial configuration, preservative status, shortage conditions, supplier reliability and clinical protocol.

What is the FDA regulatory status of ARAMINE?

Metaraminol has a long regulatory history and is marketed through legacy injectable-drug pathways rather than a contemporary novel-drug launch. The FDA’s National Drug Code Directory and DailyMed provide the most relevant public sources for identifying current labelers, presentations and marketing status (FDA, n.d.-a; DailyMed, n.d.-a).

The regulatory position has several commercial consequences:

1. The product is mature and clinically familiar.
2. The market does not depend on promotional investment by a single innovator.
3. Current commercial availability can shift when a labeler changes production or withdraws a presentation.
4. A product may remain clinically recognized under the ARAMINE name even when procurement uses a generic metaraminol label.

FDA marketing status must be assessed at the specific product and National Drug Code level. A discontinued brand presentation does not necessarily mean that metaraminol is unavailable. It may indicate that a particular manufacturer, package size or labeler has stopped commercial distribution.

How does FDA shortage status affect metaraminol?

Shortage exposure is central to the financial profile of injectable metaraminol. Sterile injectables face manufacturing risks involving active pharmaceutical ingredient supply, container availability, aseptic processing, quality-control failures and facility interruptions. FDA’s Drug Shortages database tracks product-specific availability and shortage information, but status can differ by manufacturer and presentation (FDA, n.d.-b).

When a low-volume injectable enters shortage, purchasing behavior changes quickly. Hospitals may:

• Allocate remaining inventory to emergency procedures.
• Substitute phenylephrine, ephedrine or norepinephrine.
• Accept higher contract prices for available supply.
• Shift from one vial concentration to another.
• Use pharmacy-compounded preparations where permitted.
• Add secondary suppliers to reduce operational risk.

For a mature drug such as metaraminol, shortage events can create temporary revenue increases for manufacturers with available inventory. Those gains are usually constrained by hospital contracting, regulatory controls and the ability to maintain production.

What patents protect ARAMINE and metaraminol?

The commercial ARAMINE franchise is not protected by a meaningful active patent estate. Metaraminol is an old small-molecule active ingredient, and the core composition, therapeutic use and conventional injectable formulation are long outside ordinary U.S. patent terms.

The principal exclusivity barriers are therefore regulatory and operational rather than patent-based.

Protection category	Current commercial significance
Composition-of-matter patent	No meaningful current protection expected
Original method-of-use patent	Expired or commercially immaterial
Injectable formulation patent	No material barrier identified for conventional metaraminol injection
Orphan-drug exclusivity	Not a core market feature
New chemical entity exclusivity	Expired
Pediatric exclusivity	Not commercially relevant
Biosimilar exclusivity	Not applicable
Generic approval barrier	Product-specific manufacturing and regulatory requirements

The FDA Orange Book is the principal public source for patents and exclusivity associated with approved prescription drugs (FDA, n.d.-c). Metaraminol’s economic position does not depend on Orange Book patent listings. Any current patent value would more likely arise from a specialized delivery system, combination product or new formulation rather than the established injectable itself.

Does ARAMINE have Orange Book-listed patents?

No material Orange Book patent barrier is associated with conventional metaraminol injection based on the drug’s mature status and generic availability. The relevant commercial question is not whether a generic can challenge an ARAMINE patent. It is whether a manufacturer can obtain and maintain approval for a specific injectable presentation and secure dependable sterile manufacturing capacity.

When does ARAMINE lose exclusivity?

ARAMINE’s practical exclusivity was lost decades ago. There is no current branded exclusivity period comparable to those attached to recently approved medicines.

Exclusivity type	ARAMINE status
New chemical entity exclusivity	Expired
Orphan exclusivity	Not central to the product
Patent exclusivity	Expired or immaterial
Brand-only market protection	Not present in the mature U.S. market
Generic competition	Established
Current competitive moat	Supply reliability, contracts and regulatory compliance

A manufacturer seeking to commercialize metaraminol does not generally face a Paragraph IV patent challenge directed at an active core patent. Generic entry is primarily an abbreviated new drug application, manufacturing and supply-chain issue.

Are there Paragraph IV challenges involving ARAMINE?

Publicly significant Paragraph IV litigation is not a defining feature of the metaraminol market. Paragraph IV certifications apply when an abbreviated new drug application applicant asserts that a listed patent is invalid, unenforceable or not infringed. Because metaraminol is an old injectable with no meaningful active patent moat, litigation risk is materially lower than for recently launched branded drugs (FDA, n.d.-c).

Potential disputes would be more likely to involve:

• Manufacturing quality or inspection findings.
• Product liability.
• Labeling or substitution.
• Contract disputes.
• Trade-name or trademark issues.
• Compounding and pharmacy-practice rules.
• Shortage allocation and supply obligations.

How strong is the ARAMINE patent estate?

The ARAMINE patent estate is weak as a source of exclusivity and has little apparent value as a licensing asset. The product’s defensibility depends on execution rather than intellectual property.

Strength assessment

Factor	Assessment
Core molecule protection	Very weak or expired
Formulation protection	Limited for standard injectable products
Regulatory exclusivity	Expired
Switching costs	Moderate at the institutional level because protocols and inventory systems matter
Manufacturing barriers	Moderate to high for sterile injectable production
Brand value	Limited but may persist in clinical terminology
Licensing value	Low for the legacy product; higher only for differentiated delivery or supply rights
Litigation leverage	Low on patent grounds

The manufacturing barrier is more important than the patent barrier. Sterile injectables require validated processes, particulate and sterility testing, container-closure controls, stability data and compliance with current good manufacturing practices. These requirements deter casual entry even when the active ingredient is unpatented.

Which companies compete with ARAMINE?

Competition occurs at two levels: metaraminol suppliers and therapeutic substitutes.

Direct competitors

Direct competitors include manufacturers that sell metaraminol bitartrate injection under generic labels or legacy brand references. The exact supplier set changes with product discontinuations, wholesaler inventories and regulatory status. FDA’s NDC Directory and DailyMed should be used to verify active labelers and package configurations before making procurement or investment decisions (FDA, n.d.-a; DailyMed, n.d.-a).

Therapeutic competitors

Drug	Competitive position
Phenylephrine	Common alternative for vasoconstrictor support, especially in anesthesia
Norepinephrine	Core vasopressor in critical care and shock management
Ephedrine	Used in selected anesthesia-related hypotension settings
Vasopressin	Used in defined shock and vasodilatory states
Epinephrine	Used when stronger adrenergic activity is required

Substitution is not purely price-based. Clinical protocols, onset, duration, dosing familiarity, patient condition and institutional guidelines influence selection. A metaraminol shortage can therefore shift demand to several different products rather than to one direct replacement.

What is the financial trajectory for ARAMINE?

No reliable public financial series separately reports ARAMINE revenue, units or operating margin. The product is not generally disclosed as a standalone reporting segment by publicly traded manufacturers. As a result, a precise revenue forecast would not be supportable from public information.

The financial trajectory is best described as mature, low-growth and supply-sensitive.

Financial driver	Expected effect
Routine hospital demand	Stable to modest growth
Generic price competition	Downward pressure
Shortage events	Temporary price and volume increases
New hospital protocols	Can increase or reduce utilization
Supplier exit	Raises concentration and pricing power
Sterile manufacturing investment	Increases cost base but supports continuity
Brand promotion	Limited commercial return
Patent expiry	Already reflected in market structure

Revenue is likely to be concentrated among a small number of approved suppliers at any given time. That concentration can produce volatile quarterly results, especially when one manufacturer experiences a production interruption. A supplier with available inventory may capture temporary share, but hospital contracts and subsequent competitive re-entry can reverse those gains.

The long-term financial trajectory is therefore not a branded-drug growth curve. It resembles a mature hospital injectable market with three phases:

1. Stable baseline demand from established clinical use.
2. Temporary disruption caused by shortage or supplier exit.
3. Normalization as competing supply returns or hospitals adopt substitutes.

What revenue exposure exists for manufacturers?

For manufacturers, metaraminol is more likely to be a portfolio-support product than a major revenue driver. Its value comes from filling a hospital injectable portfolio, supporting customer relationships and generating incremental contribution from existing manufacturing infrastructure.

Revenue exposure is highest for:

• A supplier with a limited number of hospital injectables.
• A manufacturer holding one of few active sources.
• A company with a contract covering major hospital systems.
• A labeler able to maintain supply during a shortage.

Revenue exposure is lower for diversified pharmaceutical companies because metaraminol would represent a small share of total sales. Public-company filings generally aggregate mature generic products into broader segments, preventing product-level valuation.

Investors should avoid using the ARAMINE name as a proxy for a large commercial franchise. The relevant valuation questions are supplier concentration, annual contract volume, manufacturing utilization, shortage duration and the company’s broader injectable portfolio.

What generic launch risks exist for metaraminol?

A new generic entrant would face several risks despite the absence of strong patent barriers.

Regulatory and technical risks

• Demonstrating product quality and sterility.
• Matching the reference product’s strength and dosage form.
• Establishing container-closure integrity.
• Validating stability and shelf life.
• Meeting FDA inspection requirements.
• Maintaining reliable active-ingredient supply.
• Avoiding particulate and contamination events.

Commercial risks

• Incumbent suppliers may cut prices after entry.
• Hospital contracts may run for multiple years.
• Wholesalers may favor established suppliers.
• Demand may be too small to support multiple manufacturers.
• Clinical substitution may limit the addressable market.
• A shortage-driven opportunity may disappear before approval.

The market can support high prices during constrained supply while remaining unattractive for permanent entry because baseline demand is limited. That distinction is important for launch planning.

What formulation patents or delivery systems could create new value?

Standard metaraminol injection has limited formulation differentiation. Potentially defensible products could involve:

• Ready-to-use prefilled syringes.
• Standardized concentrations that reduce bedside dilution.
• Premixed infusion bags.
• Extended-stability presentations.
• Closed-system transfer configurations.
• Emergency kits designed for anesthesia or critical care.

These products could obtain protection through formulation, device, packaging or method-of-use patents. Their commercial value would depend on hospital medication-safety economics, not simply on the metaraminol molecule. A product that reduces preparation errors, improves storage or shortens medication administration time may command a premium over a conventional vial.

No such differentiated ARAMINE franchise should be assumed without confirmation of a specific approved product, patent family and commercial supplier.

What licensing deals affect ARAMINE?

No major public licensing transaction is central to the current ARAMINE market profile. Legacy rights, contract manufacturing arrangements and distributor agreements may exist without being separately disclosed. The most relevant commercial arrangements are likely to be:

• Hospital group purchasing contracts.
• Wholesaler distribution agreements.
• Private-label supply arrangements.
• Contract manufacturing agreements.
• Regional product licenses.

The absence of a visible licensing transaction is consistent with an old generic injectable rather than an actively partnered innovative product.

What litigation affects ARAMINE?

Patent litigation is not the main risk category. The more relevant legal exposures are product liability, manufacturing quality, regulatory compliance, supply contracts and pharmacy-compounding rules.

A shortage can also create commercial disputes involving allocation, breach of supply commitments or substitution. These issues can affect revenue without changing the underlying patent position.

How does ARAMINE compare with phenylephrine and norepinephrine?

Factor	Metaraminol / ARAMINE	Phenylephrine	Norepinephrine
Primary use	Acute hypotension	Vasoconstrictor support, often perioperative	Shock and critical care
Market maturity	Very mature	Mature	Mature
Patent dependence	Minimal	Minimal for conventional injection	Minimal for conventional injection
Main demand channel	Hospitals and procedural care	Hospitals and anesthesia	Hospitals and intensive care
Substitution risk	High	High	Moderate to high
Shortage sensitivity	High	High	High
Differentiation opportunity	Ready-to-use and device formats	Premix and dosing convenience	Premix, stability and delivery systems
Financial profile	Small, supply-sensitive	Larger competitive market	Larger critical-care market

Metaraminol can benefit when hospitals seek an alternative to phenylephrine or ephedrine, but that benefit is usually episodic. Norepinephrine has a broader role in critical care and typically represents a larger addressable market.

What is the geographic coverage of ARAMINE?

Metaraminol availability is jurisdiction-specific. The ARAMINE name has historical recognition in the United States, while metaraminol products may be marketed under generic or different brand names in other countries. Regulatory approvals, hospital formularies, national procurement systems and local shortage conditions determine effective market access.

Geographic expansion would require country-specific approval, local pharmacovigilance, sterile manufacturing compliance and distribution capability. Because the molecule is old, the principal barrier is usually commercial registration and supply economics rather than patent clearance.

Key Takeaways

• ARAMINE is the legacy brand associated with metaraminol, an injectable vasopressor.
• The product has no meaningful current patent or regulatory exclusivity moat.
• Biosimilar competition is irrelevant because metaraminol is a small molecule.
• Public sources do not provide a reliable standalone ARAMINE revenue history.
• The market is hospital-based, generic and highly sensitive to sterile-injectable shortages.
• Financial performance depends on supplier availability, contracts, manufacturing reliability and temporary shortage pricing.
• The strongest commercial opportunities involve ready-to-use, premixed or device-enabled presentations.
• Phenylephrine and norepinephrine are major therapeutic competitors.
• Generic-entry risk is operational and commercial rather than patent-driven.
• ARAMINE is best viewed as a mature portfolio product, not a high-growth branded pharmaceutical asset.

FAQs

Is ARAMINE still sold as a branded drug?

The ARAMINE name has historical recognition, but current procurement may use generic metaraminol bitartrate injection. Product availability must be verified by specific FDA National Drug Code and labeler records.

Is metaraminol a controlled substance?

Metaraminol is a prescription vasopressor, not a controlled substance under the principal U.S. controlled-substance scheduling framework. Its use is controlled through prescription, hospital and medication-management rules.

Can hospitals substitute phenylephrine for ARAMINE?

Hospitals may use phenylephrine as a clinical alternative in appropriate cases, but substitution depends on the patient, dose, route, institutional protocol and physician judgment. The drugs are not interchangeable on a simple unit-for-unit basis.

Is metaraminol a candidate for a 505(b)(2) reformulation?

A reformulated metaraminol product could potentially use a 505(b)(2) strategy if it relies on an approved active ingredient while introducing a meaningful new dosage form, delivery system or clinical use. Commercial value would depend on differentiation and applicable exclusivity.

What is the main investment risk in metaraminol?

The main risk is insufficient baseline volume after accounting for sterile manufacturing, regulatory maintenance, hospital contracting and distribution costs. Shortage pricing can create temporary upside but does not establish a durable growth market.

References

DailyMed. (n.d.-a). Metaraminol bitartrate injection, USP prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

U.S. Food and Drug Administration. (n.d.-a). National Drug Code Directory. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory

U.S. Food and Drug Administration. (n.d.-b). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages

U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book